1. Von Dem Borne AEK, Ouwehand WH. 11 Immunology of platelet disorders. Bailliere’s clinical haematology. 1989;2(3):749-81.
2. Karpatkin S. Autoimmune thrombocytopenic purpura. 1980.
3. Chong BH. Diagnosis, treatment and pathophysiology of autoimmune thrombocytopenias. Critical reviews in oncology/hematology. 1995;20(3):271-96.
4. Lo E, Deane S. Diagnosis and classification of immunemediated thrombocytopenia. Autoimmunity reviews. 2014;13(4-5):577-83.
5. Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. Blood Transfusion. 2011;9(Suppl 2):s3.
6. Beardsley D, Tang C, Chen B-G, Lamborn C, Gomes E, Srimatkandada V. The disulfide-rich region of platelet
glycoprotein (GP) IIIa contains hydrophilic peptide sequences that bind anti-GPIIIa autoantibodies from patients with immune thrombocytopenic purpura (ITP). Biophysical chemistry. 2003;105(2-3):503-15.
7. Gillis S, Eldor A. 6 Immune thrombocytopenic purpura in adults: clinical aspects. Baillière’s clinical haematology. 1998;11(2):361-72.
8. ITP A. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(1):574-96.
9. Wu G, Jiang S, Jiang F, Zhu D, Wu H, Jiang S. Steroidal glycosides from T. terrestris. Phytochemistry. 1996;42(6):1677-81.
10. Sun W, Gao J, Tu G, Guo Z, Zhang Y. A new steroidal saponin from T. terrestris Linn. Natural Product Letters. 2002;16(4):243-7.
11. Bourke C, Stevens G, CARRIGAN MJ. Locomotor effects in sheep of alkaloids identified in Australian T. terrestris. Australian veterinary journal. 1992;69(7):163-5.
12. Conrad J, Dinchev D, Klaiber I, Mika S, Kostova I, Kraus W. A novel furostanol saponin from T. terrestris of Bulgarian origin. Fitoterapia. 2004;75(2):117-22.
13. Cai L, Wu Y, Zhang J, Pei F, Xu Y, Xie S, et al. Steroidal saponins from T. terrestris. Planta medica. 2001;67(02):196-8.
14. Nikoo M, Hasanpoor Z, Mostafaie A. Effect of T. terrestrisaqueous extract on survival and growth of human peripheral blood mononuclear cells (Hpbmc) and several cancerous cell lines. Journal of Reports in Pharmaceutical Sciences. 2015;4(1):24.
15. McCRAE K. Immune thrombocytopenia: no longer ‘idiopathic’. Cleve Clin J Med. 2011;78(6):358.
16. Li M, Wu W-K, Liu L, Liao F-L, Shinohara Y, Handa S, et al. Specific inhibiting effects of Ilexonin A on von Willebrand factor-dependent platelet aggregation under high shear rate. Chinese medical journal. 2004;117(2):241-6.
17. Bing Z, Xiaoqing L, Jinghong H. The Effects of Chicory Extract on the Levels of vWF, ET, TXA_2, PGI_2 and the Ratio of PGI_2/TXA_2 in the Rabbit Model of Hyperglycemia with Hyperlipidemia [J]. Journal of Beijing University of Traditional Chinese Medicine. 2000;6.
18. WHITE JG. The dense bodies of human platelets: inherent electron opacity of the serotonin storage particles. Blood. 1969;33(4):598-606.
19. Canobbio I, Bertoni A, Lova P, Paganini S, Hirsch E, Sinigaglia F, et al. Platelet activation by von Willebrand factor requires coordinated signaling through thromboxane A2 and FcγIIA receptor. J Biol Chem. 2001;276(28):26022-9.
20. Mercado CP, Kilic F. Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Molecular interventions. 2010;10(4):231.
21. KIMURA Y, OKUDA H, ARICHI S. Effects of various ginseng saponins on 5‐hydroxytryptamine release and aggregation in human platelets. Journal of pharmacy and pharmacology. 1988;40(12):838-43